Honokiol from Magnolia spp. induces G1 arrest via disruption of EGFR stability through repressing HDAC6 deacetylated Hsp90 function in lung cancer cells

Journal of Functional Foods

Volumn 15, Issue , 2015, Pages 84-96

  Liou, Shiuan Fu ^a   Hua, Kuo Tai ^b   Hsu, Chia Yun ^a   Weng, Meng Shih ^a  

^a FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Epidermal growth factor receptor (EGFR); Heat shock protein 90 (Hsp90); Histone deacetylase 6 (HDAC6); Honokiol; Hyper acetylation

Indexed keywords

MAGNOLIA;

EID: 84929241490     PISSN: 17564646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jff.2015.03.018     Document Type: Article

References (67)

1. Ahsan A., Hiniker S.M., Ramanand S.G., Nyati S., Hegde A., Helman A., Nyati M.K. Role of epidermal growth factor receptor degradation in cisplatin-induced cytotoxicity in head and neck cancer. Cancer Research 2010, 70(7):2862-2869. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 10.1158/0008-5472.CAN-09-4294.
2. Ahsan A., Ramanand S.G., Whitehead C., Hiniker S.M., Rehemtulla A., Pratt W.B., Nyati M.K. Wild-type EGFR is stabilized by direct interaction with HSP90 in cancer cells and tumors. Neoplasia (New York, N.Y.) 2012, 14(8):670-677. [Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S. Gov't].
3. Aldana-Masangkay G.I., Sakamoto K.M. The role of HDAC6 in cancer. Journal of Biomedicine and Biotechnology 2011, 2011:875824. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review]. 10.1155/2011/875824.
4. Amann J., Kalyankrishna S., Massion P.P., Ohm J.E., Girard L., Shigematsu H., Carbone D.P. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Research 2005, 65(1):226-235. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
5. Arteaga C. Targeting HER1/EGFR: A molecular approach to cancer therapy. Seminars in Oncology 2003, 30(3 Suppl. 7):3-14.
6. Bali P., Pranpat M., Bradner J., Balasis M., Fiskus W., Guo F., Bhalla K. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: A novel basis for antileukemia activity of histone deacetylase inhibitors. The Journal of Biological Chemistry 2005, 280(29):26729-26734. 10.1074/jbc.C500186200.
7. Butler K.V., Kozikowski A.P. Chemical origins of isoform selectivity in histone deacetylase inhibitors. Current Pharmaceutical Design 2008, 14(6):505-528.
8. Chou C.W., Wu M.S., Huang W.C., Chen C.C. HDAC inhibition decreases the expression of EGFR in colorectal cancer cells. PLoS ONE 2011, 6(3):e18087. [Research Support, Non-U.S. Gov't]. 10.1371/journal.pone.0018087.
9. Chuang D.Y., Chan M.H., Zong Y., Sheng W., He Y., Jiang J.H., Sun G.Y. Magnolia polyphenols attenuate oxidative and inflammatory responses in neurons and microglial cells. Journal of Neuroinflammation 2013, 10:15. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 10.1186/1742-2094-10-15.
10. Cooper W.A., Lam D.C., O'Toole S.A., Minna J.D. Molecular biology of lung cancer. Journal of Thoracic Disease 2013, 5(Suppl. 5):S479-S490. 10.3978/j.issn.2072-1439.2013.08.03.
11. Cote M.L., Haddad R., Edwards D.J., Atikukke G., Gadgeel S., Soubani A.O., Ethier S.P. Frequency and type of epidermal growth factor receptor mutations in African Americans with non-small cell lung cancer. Journal of Thoracic Oncology 2011, 6(3):627-630. [Comparative Study Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.]. 10.1097/JTO.0b013e31820a0ec0.
12. Cress W.D., Seto E. Histone deacetylases, transcriptional control, and cancer. Journal of Cellular Physiology 2000, 184(1):1-16. 2-7. doi:10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO. [Research Support, U.S. Gov't, P.H.S. Review].
13. Davidson M.R., Gazdar A.F., Clarke B.E. The pivotal role of pathology in the management of lung cancer. Journal of Thoracic Disease 2013, 5(Suppl. 5):S463-S478. 10.3978/j.issn.2072-1439.2013.08.43.
14. Ferrarini M., Heltai S., Zocchi M.R., Rugarli C. Unusual expression and localization of heat-shock proteins in human tumor cells. International Journal of Cancer 1992, 51(4):613-619. [Research Support, Non-U.S. Gov't].
15. Furumai R., Matsuyama A., Kobashi N., Lee K.H., Nishiyama M., Nakajima H., Horinouchi S. FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Research 2002, 62(17):4916-4921. [Research Support, Non-U.S. Gov't].
16. Gu W., Roeder R.G. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997, 90(4):595-606. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.].
17. Hirsch F.R., Varella-Garcia M., Bunn P.A., Di Maria M.V., Veve R., Bremmes R.M., Franklin W.A. Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis. Journal of Clinical Oncology 2003, 21(20):3798-3807. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. 10.1200/JCO.2003.11.069.
18. Hu J., Chen L.J., Liu L., Chen X., Chen P.L., Yang G., Wei Y.Q. Liposomal honokiol, a potent anti-angiogenesis agent, in combination with radiotherapy produces a synergistic antitumor efficacy without increasing toxicity. Experimental and Molecular Medicine 2008, 40(6):617-628. [Research Support, Non-U.S. Gov't]. 10.3858/emm.2008.40.6.617.
19. Huang W.J., Liang Y.C., Chuang S.E., Chi L.L., Lee C.Y., Lin C.W., Chen C.N. NBM-HD-1: A novel histone deacetylase inhibitor with anticancer activity. Evidence-based Complementary and Alternative Medicine 2012, 2012:781417. 10.1155/2012/781417.
20. Huang W.J., Lin C.W., Lee C.Y., Chi L.L., Chao Y.C., Wang H.N., Chen C.N. NBM-HD-3, a novel histone deacetylase inhibitor with anticancer activity through modulation of PTEN and AKT in brain cancer cells. Journal of Ethnopharmacology 2011, 136(1):156-167. [Research Support, Non-U.S. Gov't]. 10.1016/j.jep.2011.04.034.
21. Hubbert C., Guardiola A., Shao R., Kawaguchi Y., Ito A., Nixon A., Yao T.P. HDAC6 is a microtubule-associated deacetylase. Nature 2002, 417(6887):455-458. [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.]. 10.1038/417455a.
22. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA: A Cancer Journal for Clinicians 2011, 61(2):69-90. 10.3322/caac.20107.
23. Kaluza D., Kroll J., Gesierich S., Yao T.P., Boon R.A., Hergenreider E., Urbich C. Class IIb HDAC6 regulates endothelial cell migration and angiogenesis by deacetylation of cortactin. The EMBO Journal 2011, 30(20):4142-4156. [Research Support, Non-U.S. Gov't]. 10.1038/emboj.2011.298.
24. Kamemura K., Ito A., Shimazu T., Matsuyama A., Maeda S., Yao T.P., Yoshida M. Effects of downregulated HDAC6 expression on the proliferation of lung cancer cells. Biochemical and Biophysical Research Communications 2008, 374(1):84-89. [Research Support, Non-U.S. Gov't]. 10.1016/j.bbrc.2008.06.092.
25. Kobayashi N., Toyooka S., Soh J., Yamamoto H., Dote H., Kawasaki K., Miyoshi S. The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor. Lung Cancer (Amsterdam, Netherlands) 2012, 75(2):161-166. [Research Support, Non-U.S. Gov't]. 10.1016/j.lungcan.2011.04.022.
26. Kobayashi S., Boggon T.J., Dayaram T., Janne P.A., Kocher O., Meyerson M., Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. The New England Journal of Medicine 2005, 352(8):786-792. [Case Reports Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. 10.1056/NEJMoa044238.
27. Kosaka T., Yatabe Y., Endoh H., Kuwano H., Takahashi T., Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications. Cancer Research 2004, 64(24):8919-8923. [Research Support, Non-U.S. Gov't]. 10.1158/0008-5472.CAN-04-2818.
28. Kovacs J.J., Murphy P.J., Gaillard S., Zhao X., Wu J.T., Nicchitta C.V., Yao T.P. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Molecular Cell 2005, 18(5):601-607. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.]. 10.1016/j.molcel.2005.04.021.
29. Lee Y.S., Lim K.H., Guo X., Kawaguchi Y., Gao Y., Barrientos T., Yao T.P. The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis. Cancer Research 2008, 68(18):7561-7569. [Research Support, N.I.H., Extramural Research Support, U.S. Gov't, Non-P.H.S.]. 10.1158/0008-5472.CAN-08-0188.
30. Leeman-Neill R.J., Cai Q., Joyce S.C., Thomas S.M., Bhola N.E., Neill D.B., Grandis J.R. Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors. Clinical Cancer Research 2010, 16(9):2571-2579. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 10.1158/1078-0432.CCR-10-0333.
31. Liu H., Zang C., Emde A., Planas-Silva M.D., Rosche M., Kuhnl A., Eucker J. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer. European Journal of Pharmacology 2008, 591(1-3):43-51. 10.1016/j.ejphar.2008.06.026.
32. Liu W., Fan L.X., Zhou X., Sweeney W.E., Avner E.D., Li X. HDAC6 regulates epidermal growth factor receptor (EGFR) endocytic trafficking and degradation in renal epithelial cells. PLoS ONE 2012, 7(11):e49418. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 10.1371/journal.pone.0049418.
33. Marks P.A., Xu W.S. Histone deacetylase inhibitors: Potential in cancer therapy. Journal of Cellular Biochemistry 2009, 107(4):600-608. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review]. 10.1002/jcb.22185.
34. Meert A.P., Martin B., Verdebout J.M., Noel S., Ninane V., Sculier J.P. Is there a relationship between c-erbB-1 and c-erbB-2 amplification and protein overexpression in NSCLC?. Lung Cancer (Amsterdam, Netherlands) 2005, 47(3):325-336. [Research Support, Non-U.S. Gov't]. 10.1016/j.lungcan.2004.07.047.
35. Minamiya Y., Ono T., Saito H., Takahashi N., Ito M., Mitsui M., Ogawa J. Expression of histone deacetylase 1 correlates with a poor prognosis in patients with adenocarcinoma of the lung. Lung Cancer (Amsterdam, Netherlands) 2011, 74(2):300-304. 10.1016/j.lungcan.2011.02.019.
36. Mok T.S., Wu Y.L., Thongprasert S., Yang C.H., Chu D.T., Saijo N., Fukuoka M. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. The New England Journal of Medicine 2009, 361(10):947-957. [Clinical Trial, Phase III Comparative Study Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't]. 10.1056/NEJMoa0810699.
37. Mollapour M., Neckers L. Post-translational modifications of Hsp90 and their contributions to chaperone regulation. Biochimica et Biophysica Acta 2012, 1823(3):648-655. [Research Support, N.I.H., Intramural Review]. 10.1016/j.bbamcr.2011.07.018.
38. Newman D.J., Cragg G.M., Snader K.M. Natural products as sources of new drugs over the period 1981-2002. Journal of Natural Products 2003, 66(7):1022-1037. 10.1021/np030096l.
39. Normanno N., De Luca A., Bianco C., Strizzi L., Mancino M., Maiello M.R., Salomon D.S. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006, 366(1):2-16. [Research Support, Non-U.S. Gov't Review]. 10.1016/j.gene.2005.10.018.
40. Park E.J., Min H.Y., Chung H.J., Hong J.Y., Kang Y.J., Hung T.M., Lee S.K. Down-regulation of c-Src/EGFR-mediated signaling activation is involved in the honokiol-induced cell cycle arrest and apoptosis in MDA-MB-231 human breast cancer cells. Cancer Letters 2009, 277(2):133-140. [Research Support, Non-U.S. Gov't]. 10.1016/j.canlet.2008.11.029.
41. Park J.H., Kim S.H., Choi M.C., Lee J., Oh D.Y., Im S.A., Kim T.Y. Class II histone deacetylases play pivotal roles in heat shock protein 90-mediated proteasomal degradation of vascular endothelial growth factor receptors. Biochemical and Biophysical Research Communications 2008, 368(2):318-322. [Research Support, Non-U.S. Gov't]. 10.1016/j.bbrc.2008.01.056.
42. Pick E., Kluger Y., Giltnane J.M., Moeder C., Camp R.L., Rimm D.L., Kluger H.M. High HSP90 expression is associated with decreased survival in breast cancer. Cancer Research 2007, 67(7):2932-2937. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 10.1158/0008-5472.CAN-06-4511.
43. Robey R.W., Chakraborty A.R., Basseville A., Luchenko V., Bahr J., Zhan Z., Bates S.E. Histone deacetylase inhibitors: Emerging mechanisms of resistance. Molecular Pharmaceutics 2011, 8(6):2021-2031. [Research Support, N.I.H., Intramural Review]. 10.1021/mp200329f.
44. Rosell R., Moran T., Queralt C., Porta R., Cardenal F., Camps C., Taron M. Screening for epidermal growth factor receptor mutations in lung cancer. The New England Journal of Medicine 2009, 361(10):958-967. [Evaluation Studies Multicenter Study Research Support, Non-U.S. Gov't]. 10.1056/NEJMoa0904554.
45. Santo L., Hideshima T., Kung A.L., Tseng J.C., Tamang D., Yang M., Raje N. Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood 2012, 119(11):2579-2589. 10.1182/blood-2011-10-387365.
46. Sasaki H., Moriyama S., Nakashima Y., Kobayashi Y., Kiriyama M., Fukai I., Fujii Y. Histone deacetylase 1 mRNA expression in lung cancer. Lung Cancer (Amsterdam, Netherlands) 2004, 46(2):171-178. 10.1016/j.lungcan.2004.03.021.
47. Sawai A., Chandarlapaty S., Greulich H., Gonen M., Ye Q., Arteaga C.L., Solit D.B. Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel. Cancer Research 2008, 68(2):589-596. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 10.1158/0008-5472.CAN-07-1570.
48. Scroggins B.T., Robzyk K., Wang D., Marcu M.G., Tsutsumi S., Beebe K., Neckers L. An acetylation site in the middle domain of Hsp90 regulates chaperone function. Molecular Cell 2007, 25(1):151-159. [Research Support, N.I.H., Intramural]. 10.1016/j.molcel.2006.12.008.
49. Shimamura T., Li D., Ji H., Haringsma H.J., Liniker E., Borgman C.L., Shapiro G.I. Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Research 2008, 68(14):5827-5838. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 10.1158/0008-5472.CAN-07-5428.
50. Shimamura T., Lowell A.M., Engelman J.A., Shapiro G.I. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Research 2005, 65(14):6401-6408. [Research Support, N.I.H., Extramural Research Support, U.S. Gov't, P.H.S. 10.1158/0008-5472.CAN-05-0933.
51. Singh T., Prasad R., Katiyar S.K. Inhibition of class I histone deacetylases in non-small cell lung cancer by honokiol leads to suppression of cancer cell growth and induction of cell death in vitro and in vivo. Epigenetics 2013, 8(1):54-65. [Research Support, U.S. Gov't, Non-P.H.S.]. 10.4161/epi.23078.
52. Somoza J.R., Skene R.J., Katz B.A., Mol C., Ho J.D., Jennings A.J., Tari L.W. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure (London, England: 1993) 2004, 12(7):1325-1334. [Research Support, U.S. Gov't, Non-P.H.S.]. 10.1016/j.str.2004.04.012.
53. Sun Y., Chin Y.E., Weisiger E., Malter C., Tawara I., Toubai T., Reddy P. Cutting edge: Negative regulation of dendritic cells through acetylation of the nonhistone protein STAT-3. The Journal of Immunology 2009, 182(10):5899-5903. [Research Support, N.I.H., Extramural]. 10.4049/jimmunol.0804388.
54. Suzuki T. Explorative study on isoform-selective histone deacetylase inhibitors. Chemical and Pharmaceutical Bulletin 2009, 57(9):897-906. [Research Support, Non-U.S. Gov't Review].
55. Trepel J., Mollapour M., Giaccone G., Neckers L. Targeting the dynamic HSP90 complex in cancer. Nature Reviews. Cancer 2010, 10(8):537-549. 10.1038/nrc2887.
56. Wang X., Duan X., Yang G., Zhang X., Deng L., Zheng H., Chen L. Honokiol crosses BBB and BCSFB, and inhibits brain tumor growth in rat 9L intracerebral gliosarcoma model and human U251 xenograft glioma model. PLoS ONE 2011, 6(4):e18490. [Research Support, Non-U.S. Gov't]. 10.1371/journal.pone.0018490.
57. Wilson A.J., Byun D.S., Popova N., Murray L.B., L'Italien K., Sowa Y., Mariadason J.M. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. The Journal of Biological Chemistry 2006, 281(19):13548-13558. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't]. 10.1074/jbc.M510023200.
58. Witt O., Deubzer H.E., Milde T., Oehme I. HDAC family: What are the cancer relevant targets?. Cancer Letters 2009, 277(1):8-21. [Research Support, Non-U.S. Gov't Review]. 10.1016/j.canlet.2008.08.016.
59. Wu S.G., Chang Y.L., Hsu Y.C., Wu J.Y., Yang C.H., Yu C.J., Yang P.C. Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern. The Oncologist 2008, 13(12):1276-1284. [Research Support, Non-U.S. Gov't]. 10.1634/theoncologist.2008-0093.
60. Yamaguchi T., Cubizolles F., Zhang Y., Reichert N., Kohler H., Seiser C., Matthias P. Histone deacetylases 1 and 2 act in concert to promote the G1-to-S progression. Genes and Development 2010, 24(5):455-469. [Research Support, Non-U.S. Gov't]. 10.1101/gad.552310.
61. Yang X.J., Seto E. The Rpd3/Hda1 family of lysine deacetylases: From bacteria and yeast to mice and men. Nature Reviews. Molecular Cell Biology 2008, 9(3):206-218. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review]. 10.1038/nrm2346.
62. Yang Y., Rao R., Shen J., Tang Y., Fiskus W., Nechtman J., Bhalla K. Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion. Cancer Research 2008, 68(12):4833-4842. [Research Support, Non-U.S. Gov't]. 10.1158/0008-5472.CAN-08-0644.
63. Yoon Y.K., Kim H.P., Han S.W., Oh do Y., Im S.A., Bang Y.J., Kim T.Y. KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: Implication for combinatorial approach. Molecular Carcinogenesis 2010, 49(4):353-362. [Research Support, Non-U.S. Gov't]. 10.1002/mc.20607.
64. Yu S.Y., Liao C.H., Chien M.H., Tsai T.Y., Lin J.K., Weng M.S. Induction of p21(Waf1/Cip1) by garcinol via downregulation of p38-MAPK signaling in p53-independent H1299 lung cancer. Journal of Agricultural and Food Chemistry 2014, 62(9):2085-2095. [Research Support, Non-U.S. Gov't]. 10.1021/jf4037722.
65. Zhang B., Maniatis T., Song Y., Zhang W., Zhang X., Li N., Roberts A. Evaluation of magnolia bark extract in chromosomal aberration assays. Mutation Research 2008, 654(2):133-137. [Research Support, Non-U.S. Gov't]. 10.1016/j.mrgentox.2008.05.009.
66. Zhang P., Liu X., Zhu Y., Chen S., Zhou D., Wang Y. Honokiol inhibits the inflammatory reaction during cerebral ischemia reperfusion by suppressing NF-kappaB activation and cytokine production of glial cells. Neuroscience Letters 2013, 534:123-127. [Research Support, Non-U.S. Gov't]. 10.1016/j.neulet.2012.11.052.
67. Zhou Q., Agoston A.T., Atadja P., Nelson W.G., Davidson N.E. Inhibition of histone deacetylases promotes ubiquitin-dependent proteasomal degradation of DNA methyltransferase 1 in human breast cancer cells. Molecular Cancer Research 2008, 6(5):873-883. [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S.]. 10.1158/1541-7786.MCR-07-0330.